Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Review Of Pfizer’s Maraviroc Will Reflect CCR5 Antagonist Class Safety Issues

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Antiviral Drugs Advisory Committee will also assess whether existing data supports accelerated approval for the first-in-class HIV therapy.

You may also be interested in...



Pfizer’s Maraviroc Deemed “Approvable” By FDA

Pfizer says it is working with FDA to finalize product labeling for the HIV treatment as soon as possible.

Pfizer’s Maraviroc Deemed “Approvable” By FDA

Pfizer says it is working with FDA to finalize product labeling for the HIV treatment as soon as possible.

Pfizer’s Maraviroc Unanimously Recommended For Accelerated Approval

However, members of FDA’s Antiviral Drugs Advisory Committee voice numerous concerns, recommending additional data or analysis for full approval of the CCR5 antagonist.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065943

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel